Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.
Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, Nappo F, Businello G, Sbaraglia M, Bergamo F, Spolverato G, Pucciarelli S, Merigliano S, Pilati P, Cavallin F, Realdon S, Farinati F, Dei Tos AP, Zagonel V, Lonardi S, Loupakis F, Fassan M. Pellino A, et al. Among authors: murgioni s. J Pers Med. 2021 Oct 26;11(11):1095. doi: 10.3390/jpm11111095. J Pers Med. 2021. PMID: 34834447 Free PMC article.
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study.
Schirripa M, Pasqualetti G, Giampieri R, Scartozzi M, Lonardi S, Rumanò L, Bergamo F, Stragliotto S, Murgioni S, Alberti G, Rizzato MD, Prete AA, Puzzoni M, Pusceddu V, Ziranu P, Pani F, Mariotti S, Zagonel V, Monzani F, Loupakis F. Schirripa M, et al. Among authors: murgioni s. Clin Colorectal Cancer. 2018 Sep;17(3):e601-e615. doi: 10.1016/j.clcc.2018.05.013. Epub 2018 Jun 8. Clin Colorectal Cancer. 2018. PMID: 30149875
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib.
Schirripa M, Borelli B, D'Aurizio R, Lubrano S, Cremolini C, Zucchelli G, Antoniotti C, Marmorino F, Prete AA, Murgioni S, Bergamo F, Zagonel V, Tuccoli A, Marranci A, Rizzo M, Tedeschi L, Magnoni L, Falcone A, Loupakis F, Poliseno L. Schirripa M, et al. Among authors: murgioni s. Pharmacogenomics J. 2019 Oct;19(5):455-464. doi: 10.1038/s41397-019-0075-3. Epub 2019 Jan 28. Pharmacogenomics J. 2019. PMID: 30686821
Ramucirumab: the long and winding road toward being an option for mCRC treatment.
Debeuckelaere C, Murgioni S, Lonardi S, Girardi N, Alberti G, Fano C, Gallimberti S, Magro C, Ahcene-Djaballah S, Daniel F, Fassan M, Prenen H, Loupakis F. Debeuckelaere C, et al. Among authors: murgioni s. Expert Opin Biol Ther. 2019 May;19(5):399-409. doi: 10.1080/14712598.2019.1600505. Epub 2019 Apr 16. Expert Opin Biol Ther. 2019. PMID: 30917706 Review.
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.
Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. Loupakis F, et al. Among authors: murgioni s. J Immunother Cancer. 2019 Nov 8;7(1):297. doi: 10.1186/s40425-019-0788-5. J Immunother Cancer. 2019. PMID: 31703605 Free PMC article.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: murgioni s. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial.
Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Murgioni S, Lonardi S, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Barzi A, Loupakis F, Falcone A, Lenz HJ. Suenaga M, et al. Among authors: murgioni s. Cancers (Basel). 2020 Jun 30;12(7):1742. doi: 10.3390/cancers12071742. Cancers (Basel). 2020. PMID: 32629861 Free PMC article.
Treatment personalization in gastrointestinal neuroendocrine tumors.
Borga C, Businello G, Murgioni S, Bergamo F, Martini C, De Carlo E, Trevellin E, Vettor R, Fassan M. Borga C, et al. Among authors: murgioni s. Curr Treat Options Oncol. 2021 Feb 27;22(4):29. doi: 10.1007/s11864-021-00825-4. Curr Treat Options Oncol. 2021. PMID: 33641005 Review.
34 results